Vaccines for the prevention of neglected diseases - dengue fever

被引：14

作者：

Pang, TK ^{[1
]}

机构：

[1] WHO, Res Policy & Cooperat, CH-1211 Geneva 27, Switzerland

来源：

CURRENT OPINION IN BIOTECHNOLOGY | 2003年 / 14卷 / 03期

关键词：

D O I：

10.1016/S0958-1669(03)00061-2

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Dengue and dengue hemorrhagic fever have spread to all tropical areas of the developing world, but still remain largely neglected diseases. Several promising vaccine candidates in the form of live attenuated and chimeric vaccines have been developed and are currently in human clinical trials. However, significant practical, logistic, and scientific challenges remain before these vaccines can widely and safely be applied to vulnerable populations. Vector control, community education and public health measures must be pursued in parallel with vaccine development.

引用

页码：332 / 336

页数：5

共 31 条

[11]

Guzmán María G., 2002, Rev Panam Salud Publica, V11, P223, DOI 10.1590/S1020-49892002000400003

[12] Dengue:: an update [J].

Guzmán, MG ;

Kouri, G .

LANCET INFECTIOUS DISEASES, 2002, 2 (01) :33-42

[13] The future of dengue vaccines [J].

Halstead, SB ;

Deen, J .

LANCET, 2002, 360 (9341) :1243-1245

[14] Growth characteristics of ChimeriVaxTM-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes [J].

Johnson, BW ;

Chambers, TV ;

Crabtree, MB ;

Bhatt, TR ;

Guirakhoo, F ;

Monath, TP ;

Miller, BR .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2002, 67 (03) :260-265

[15] Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers [J].

Kanesa-thasan, N ;

Sun, W ;

Kim-Ahn, G ;

Van Albert, S ;

Putnak, JR ;

King, A ;

Raengsakulsrach, B ;

Christ-Schmidt, H ;

Gilson, K ;

Zahradnik, JM ;

Vaughn, DW ;

Innis, BL ;

Saluzzo, JF ;

Hoke, CH .

VACCINE, 2001, 19 (23-24) :3179-3188

[16] Control of Aedes vectors of dengue in three provinces of Vietnam by use of Mesocyclops (Copepoda) and community-based methods validated by entomologic, clinical, and serological surveillance [J].

Kay, BH ;

Nam, VS ;

Van Tien, T ;

Yen, NT ;

Phong, TV ;

Diep, VTB ;

Ninh, TU ;

Bektas, A ;

Aaskov, JG .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2002, 66 (01) :40-48

[17] Development of new vaccines against dengue fever and Japanese encephalitis [J].

Kinney, RM ;

Huang, CYH .

INTERVIROLOGY, 2001, 44 (2-3) :176-197

[18] Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever [J].

Kochel, TJ ;

Watts, DM ;

Halstead, SB ;

Hayes, CG ;

Espinoza, A ;

Felices, V ;

Caceda, R ;

Bautista, CT ;

Montoya, Y ;

Douglas, S ;

Russe, KL .

LANCET, 2002, 360 (9329) :310-312

[19] Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine [J].

Konishi, E ;

Fujii, A .

VACCINE, 2002, 20 (7-8) :1058-1067

[20] Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren [J].

Mangada, MM ;

Endy, TP ;

Nisalak, A ;

Chunsuttiwat, S ;

Vaughn, DW ;

Libraty, DH ;

Green, S ;

Ennis, FA ;

Rothman, AL .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (12) :1697-1703

← 1 2 3 4 →